TY  - JOUR
T1  - A Placebo Controlled Assessing the Effects of Statin on Echocardiography Function and Morbidity and Mortality in Patients with Heart Failure
AU - , Vida Nesar Hosseini 
JO  - Research Journal of Biological Sciences
VL  - 3
IS  - 4
SP  - 356
EP  - 360
PY  - 2008
DA  - 2001/08/19
SN  - 1815-8846
DO  - rjbsci.2008.356.360
UR  - https://makhillpublications.co/view-article.php?doi=rjbsci.2008.356.360
KW  - Statin
KW  -mortality
KW  -morbidity
KW  -Chronic Heart Failure (CHF)
KW  -Echocardiography
KW  -EJection Fraction (EF) Left Ventricular End- Diastole Volume (LVEDV)
KW  -Left Ventricular End- Systolic Volum (LVESV) Placebo (PLB)
AB  - This study investigates the effects of statin on left ventricular ejection fraction and mortality and morbidity in patients with heart failure for one year. The function of LV is detecting the survival of patients with CHF. So we use statin in those with previously stable CHF. A total of 200 patients with L.VEF = 40% were randomized for one year with statin (20 mg) (n= 100) or placebo (n = 100) in addition to routine treatment for CHF. The end point of this study is the effect of statin on LV EF and mortality and morbidity of patients with CHF. The LV EF was similar in both groups at base line (statin :35 ±6% PLB: 35±7% ) and after one year of treatment ( mean difference 1.49% p = 0.1) there were significantly more adjudicated morbidity in the placebo group (n = 28[25%]), statin (n = 10[8%] p = 0.005) but no significant difference between group for mortality. A proportion of patients withdrew from each treatment group because of (incomplete follow). After one year treatment. Statin group improved symptoms and morbidity than PLB groups, but didn’t change mortality and LVEF. A randomized placebo controlled trial assessing the effects of statin on echocardiography function and mortality and morbidity in patients with LVEF = 40%. We compared the effect of statin with placebo on cardiac function in patients with congestive heart failure. Statin treatment affect left ventricular ejection fraction compared with placebo ( mean difference-0.65% , p<0.0001)  and significant improvements in morbidity but no affect on mortality (mean difference 1.50% p = 0.1).
ER  -